Avista Healthcare Public Acquisition Corp.
Status: Deal Closed
U=S+W
W=S/2@11.5
IPO Proceeds, $M | $310.00M |
---|---|
IPO Date | Oct 11, 2016 |
CEO | David Burgstahler |
Left Lead | Credit Suisse |
IPO Cash in Trust | 100.0% |
SPAC Tenor | 24+[4] |
IPO Sector |
Healthcare
Healthcare (North America or Europe) |
IPO Geography | Global |
Target Company | Organogenesis |
Deal Announced | Aug 17, 2018 |
Deal Size, $M | $673.00M |
Deal Sector | Healthcare |
Deal Geography | US/Canada |
SEC Filings | www.sec.gov |
Approval Vote | Dec 10, 2018 |
Amendment Vote | TBD |
Closing Date | Dec 11, 2018 |
Formerly AHPA
ORGO
ORGOW
Price | $3.81 |
---|---|
Last closing price | $3.97 |
H/L, today | $3.73 / $3.97 |
H/L, 52-week | $1.80 / $4.50 |
Volume, today | 2,343,361 |
Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in for more on Avista Healthcare Public Acquisition Corp.:
- Structure and cap table
- 8 directors & officers
- 47 filings and events
- 2 underwriters
- 1 deal advisors
- 2 legal advisors
Structure
Sign in to view structure, cap table, and calendar of events.
Team
Name | Age | Title |
---|---|---|
Thompson Dean | 58 | Executive Chairman |
David Burgstahler | 48 | President, CEO & Director |
John Cafasso | 44 | CFO |
Benjamin Silbert | 46 | General Counsel & Secretary |
Håkan Björklund | 60 | Director |
Charles Harwood | 63 | Director |
Brian Markison | 57 | Director |
Robert O'Neil | 66 | Director |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
Underwriters
Credit Suisse | BR | 29,250,000 | units |
I-Bankers Securities | 750,000 | ||
30,000,000 | units | ||
Up-Front UW fee | 2.00 | % | |
Deferred UW fee |
3.50 | % |
Sign in to view more advisor data.
Deal
Sign in to view merger details and deal financials.